Skip to main content

Table 1 Summary characteristics of included trials

From: Effect of tranexamic acid on thrombotic events and seizures in bleeding patients: a systematic review and meta-analysis

  No. of trials
n = 234
No. of participants
n = 102,681
Trial characteristics   
Multicenter study 26 80,268
Single-center study 208 22,413
Patient disease type   
Trauma (including traumatic brain injury) 7 34,488
Obstetrics and gynecology 22 28,089
Cardiac surgery 47 10,528
Orthopedic surgery 124 11,353
Intracranial (non-traumatic) hemorrhage 9 4057
Gastrointestinal hemorrhage 3 12,312
Others 22 1854
Patient characteristics   
Mean age (year) of trial arms, median [IQR] Control: 54 [43–66]
Intervention: 50 [46–67]
Percentage of female patients in trial arms, median [IQR] Control: 54 [35–70]
Intervention: 53 [31–73]
Adults 225 101,917
Pediatrics 9 764
TXA dose   
2 g/day 180 78,268
2 g/day < TXA dose 4 g/day 14 13,887
> 4 g 20 7603
Composite 20 2923
TXA regimen   
Bolus administration 149 47,973
Continuous infusion 4 785
Bolus + infusion 80 53,848
  1. IQR, interquartile range. TXA, tranexamic acid